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Abstract 
Background: Studies suggest that people with bronchiectasis are at increased risk of 
cardiovascular co-morbidities. We aimed to quantify the relative risk of incident 
cardiovascular events following a respiratory tract infection amongst people with 
bronchiectasis. 
Methods: Using UK electronic primary care records, we conducted a within-person 
comparison using the self-controlled case series method. We calculated the relative risk of 
first time cardiovascular events (either first myocardial infarction [MI] or stroke) following a 
respiratory tract infection compared with the individual’s baseline risk. 
Results: Our cohort consisted of 895 individuals with non-CF bronchiectasis with a first MI or 
stroke and at least one respiratory tract infection. There was an increased rate of first time 
cardiovascular events in the 91 day period after a respiratory tract infection (Incidence Rate 
Ratio [IRR] 1.56; 95% CI 1.20 to 2.02).  The rate of a first cardiovascular event was highest in 
the first three days following a respiratory tract infection (IRR 2.73, 95% CI 1.41 to 5.27).  
 Conclusions: These data suggest that respiratory tract infections are strongly associated with 
a transient increased risk of first time MI or stroke amongst people with bronchiectasis. As 
respiratory tract infections are six times more common in people with bronchiectasis than 
the general population, the increased risk has a disproportionately greater impact in these 
individuals. These findings may have implications for including cardiovascular risk 
modifications in airway infection treatment pathways in this population. 
 
(225 words) 
Introduction 
Bronchiectasis is a suppurative chronic lung disease characterized by repeated infections, and 
recent studies have shown that the incidence and prevalence of bronchiectasis in the UK [1] 
and USA [2] is increasing.  Previous studies in the general population [3-5] and in people with 
COPD[6] have established an association between respiratory tract infections and 
cardiovascular events, and in previous work we have shown that  people with bronchiectasis 
experience more cardiovascular co-morbidities compared to the general population.[7] It has 
been suggested that repeated lower respiratory tract infections result in an acute phase 
response and increased systemic inflammation which contributes to the increased 
cardiovascular risk seen. Although it is likely this association could be generalized to 
individuals with bronchiectasis, the occurrence of respiratory tract infections amongst people 
with bronchiectasis is far higher, and results in substantial morbidity and mortality. Hence 
quantifying the effect and magnitude of cardiovascular events following a respiratory tract 
infection is important. 
Using routinely collected, anonymized UK primary care data, we conducted a within person 
comparison to assess the impact of respiratory tract infections on the risk of incident 
cardiovascular events amongst people with non-CF bronchiectasis.  
 
 
 
 
 
Methods 
Data source 
We used anonymized electronic primary care data from the Clinical Practice Research 
Datalink (CPRD) (www.cprd.com). Information is recorded as part of routine care, and 
includes diagnostic and prescribing information.  Studies have previously demonstrated that 
individuals who contribute to CPRD are broadly representative of UK general population.[8] 
Approval was obtained from the Independent Scientific Advisory Committee (ISAC), which 
oversees research involving CPRD data (protocol ref: 13_030R; available on request) 
Study population 
Our study population consisted of a dynamic cohort of individuals with a recorded diagnosis 
of bronchiectasis who were alive and contributing to CPRD at any point between the 1st of 
January 2000 and 31st of December 2013. We identified individuals with a record of 
bronchiectasis using pre-defined Read codes (H34..00, H34z.00, H340.00, A115.00, H341.00, 
P86.100) that have been previously been used in epidemiological studies.[1, 7] We excluded 
people with a co-existing diagnosis of cystic fibrosis (CF), anyone under 18 years of age at time 
of diagnosis and individuals who only had a record of bronchiectasis at time of death. All 
individuals had at least 12 months of electronic records that were of research quality prior to 
entry into the study. The start of our observation period was the latest of study start date or 
date of diagnosis of bronchiectasis. The end of the study observation period was the earliest 
of date of death, transfer out of practice, last date of data collection or study end date. 
 
 
Definition of outcomes 
Our primary outcome was first record of a cardiovascular event, a composite outcome of first 
recorded diagnosis of myocardial infarction (MI) or stroke that occurred during the study 
observation period. Individuals with diagnoses of MI or stroke prior to the start of the study 
period were excluded (see Figure 1). The validity of recording of MI [9, 10] and stroke [10, 11] 
in electronic primary care records has previously been shown to be high. MI and stroke events 
that coincided with date of death were also excluded. One of the assumptions of the self–
controlled case series method is that the outcome of interest must not censor the observation 
period. In our case, if a cardiovascular event increases the likelihood of death. However, there 
is evidence that the method is robust to this assumption.[12] We restricted out outcomes 
events to non-fatal MI and strokes to overcome this potential bias. Our secondary outcomes 
were incident MI and stroke events analyzed separately.  
 
Definition of respiratory tract infection 
We searched medical records for diagnoses of respiratory tract infections. The medical Read 
Codes used to identify respiratory tract infections were developed by two clinical 
epidemiologists, one of whom was a consultant respiratory physician[13], and were 
consistent with the United Kingdom’s National Institute of Health and Care Excellence (NICE) 
guidelines for the diagnosis of lower respiratory tract infection and clinical diagnosis of 
community acquired pneumonia.[14] We excluded Read Codes suggestive of an exacerbation 
of chronic obstructive pulmonary disease (COPD)[15] as we have previously demonstrated 
that approximately 1/3rd of individuals with bronchiectasis also have a co-existing diagnosis 
of COPD.[1]  Codes used to define respiratory tract infection can be found in the appendix 
and included report of these codes with and without treatment with antibiotics either by the 
GP (i.e. treated at home) or in hospital. Date of the respiratory tract infection was deemed to 
be the date the patient visited the GP or hospital as was recorded in the electronic medical 
record. 
 
Statistical analysis 
We undertook a within person comparisons in our population of individuals with 
bronchiectasis who had both a first cardiovascular outcome and at least one  respiratory tract 
infection during our study observation period. The self-controlled case series study design is 
similar with cohort methodology and is adapted from rate modelling using a Poisson 
distribution. This study design relies on within person comparisons in a population with both 
the exposure and outcome of interest.[12, 16] An advantage of the within person comparison 
method is that possible confounders such as smoking habit, hypertension, hyperlipidemia and 
diabetes mellitus, are removed.  
The self-controlled case series method relies on several assumptions, an important one being 
that the occurrence of the outcome event should not alter the probability of subsequent 
exposure. In this study, a cardiovascular event should not change the subsequent probability 
of developing a respiratory tract infection. Such a change would alter the baseline rate of 
events and this may result in an over or under estimate of the relative rate of events occurring 
in exposed periods compared to baseline periods. If there is a transient change in the 
probability of post-outcome exposures, this bias can be overcome by removing a predefined 
period of time before exposure from all other baseline periods. [17] In our study, a two week 
period prior to first record of a respiratory tract infection was removed from the baseline 
period.  All assumptions of the self-controlled case series method are detailed in Appendix 1.  
Fixed effects conditional Poisson regression was used to generate incidence rate ratios 
comparing the rate of incident cardiovascular events during our pre-specified high risk 
intervals following a respiratory tract infection compared with all other observed periods for 
each individual. Our high risk interval was defined as extending up to 91 days after a 
respiratory tract infection, subdivided in to smaller periods of 1 to 3 days, 4 to 7 days, 8 to 14 
days, 15 to 29 days and 29 to 91 days after an infection. These risk windows have previously 
been used to evaluate the risk of MI and stroke following acute infections in the general 
population.[4]  For people who had repeated respiratory tract infections during the study 
observation period, each episode of infection was followed by a 91 day interval, subdivided 
into the smaller periods mentioned above, where individuals were considered at high risk.  
For those who had multiple records of respiratory tract infections within the high risk interval, 
only the first record of infection was used to define the start and end of the high risk interval.  
Since age varies with time, we adjusted for age in five year age bands over the age of 45. As 
seasonal patterns are seen in both cardiovascular events and respiratory tract infections, we 
then repeated the analyses controlling for the effect of seasonal variation by dividing up the 
study observation period into warmer months (April to September) and cooler months 
(October to March). 
Secondary analyses 
We repeated the analyses for the individual outcomes of first MI and stroke, in turn. Finally, 
we also explored the impact of co-existing COPD in the association of cardiovascular 
outcomes following a respiratory tract infection. The main analyses were repeated after 
excluding people with bronchiectasis who also had a diagnosis of COPD.  
Power calculation 
Prior to undertaking the analyses, we expected to identify approximately 800 individuals with 
bronchiectasis who had an incident cardiovascular event and at least one respiratory tract 
infection. With this sample size we calculated that we would have more than 80% power at 
5% significance level to detect an incidence rate ratio of 1.5 or above in the first two weeks 
after an infection. All statistical analyses were conducted using Stata version 14 (Texas).  
Results 
From a cohort of 26,518 individuals with bronchiectasis, our final study population consisted 
of 895 individuals with bronchiectasis who had both a first cardiovascular event and at least 
one respiratory tract infection during the study observation period. (See Figure 1). 468 
(52.9%) people were female, the median age at time of diagnosis of bronchiectasis was 63.7 
years (Interquartile range [IQR] 50.0 to 72.1) and 235 (26.3%)were current -smokers (see 
Table 1). The mean observation period for the study population was 6.2 years (standard 
deviation [SD] 4.5). After controlling for the effects of age, the rate of incident cardiovascular 
events was 56% higher in the 91 day period after a record of respiratory tract infection 
(Incidence Rate Ratio [IRR] 1.56, 95% Confidence Interval [CI] 1.20 to 2.02).  The rate of a first 
cardiovascular event was highest in the first three days following a respiratory tract infection 
(IRR 2.73, 95% CI 1.41 to 5.27) and fell after the first fourteen days (see Table 2). The rate of 
incident cardiovascular events remained higher after a respiratory tract infection after 
controlling for the effects on seasonality (see Table 2). 
Secondary analyses 
443 people with bronchiectasis had an incident myocardial infarction and least one episode 
of a respiratory tract infection during our study period. The age adjusted rate ratio for first 
myocardial infarction was substantially higher in the fourteen days following a respiratory 
tract infection compared to periods without a respiratory tract infection. The rate ratio for 
first MI peaked in the first three days following a respiratory tract infection where it was over 
four times higher compared to baseline (see Table 3).  479 individuals with bronchiectasis and 
at least one respiratory tract infection had an incident stroke. The age adjusted rate ratio for 
first stroke was also higher after a respiratory tract infection, and was highest in the first three 
days (IRR 1.79, 95% CI 1.20-3.53); see Table 4). Additional adjustment for seasonality had little 
impact on the rate ratios for first MI and stroke (see Tables 3 and 4). After excluding 
individuals with co-existing COPD (n=464), we found marginal change to the age adjusted rate 
of incident cardiovascular events following a respiratory tract infection (see Table 5). 
Controlling for the effects of season in addition to age did not alter the rate ratios for incident 
cardiovascular event in this subset.  
Due to the fact the SCCS is usually undertaken in studies of shorter follow up, we stratified 
the analysis on people with < and > 6 years FU since this is the mean and found the IRR is 
similar, between the two, suggesting the result is not being driven by unadjusted 
confounding amongst people with longer FU (Table 2b in Supplementary material). We also 
repeated the analysis using calendar year, 2 year age bands and season (Table 2a 
Supplementary material).   
 
 
 
 
 
  
 
Figure 1: Identification of study population 
 
 
 
 
 
Figure 2: Pictorial representation of the SCCS  
  
 
 
 
 
 
 
 
 
 
Table 1: Baseline characteristics of the bronchiectasis cohort 
Characteristic  Number of people (n=895) 
Sex (%) Male 427 (47.1) 
 Female 468 (52.9) 
Age category (years) (%) <45 146 (16.3) 
 45-55 114 (12.7) 
 56-65 187 (20.9) 
 66-75 248 (27.7) 
 >75 200 (22.4) 
Mean observation period (years) 
(Standard deviation [SD]) 
 6.2 (4.5) 
Median number of respiratory 
tract infections during the study 
period (Interquartile range [IQR]) 
 5 (2-10) 
Smoking habit (%) Never smoked 165 (18.4) 
 Ex-smoker 478 (53.4) 
 Current smoker 235 (26.3) 
 Missing information 17 (1.9) 
 
 
Table 2: Adjusted incidence rate ratios of a first cardiovascular event in risk periods after a 
respiratory tract infection 
Risk period Number of events  IRR (95% CI)* IRR (95% CI) # 
1-91 days 125 1.56 (1.20 to 2.02) 1.25 (1.02-1.53) 
1-3 days 82 2.73 (1.41-5.27) 2.39 (1.21-5.62) 
4-7 days 21 2.13 (1.46-2.74) 2.01 (1.22-2.78) 
8-14 days 9 1.93 (1.11-2.08) 1.73 (1.09-2.13) 
15-28 days 8 1.36 (0.87-2.11) 1.16 (0.77-2.19) 
29-91 days 5 1.19 (0.73-1.51) 1.08 (0.69-1.53) 
Baseline period 706 1.00 1.00 
*Incidence Rate Ratio adjusted for age                                                #Incidence Rate Ratio adjusted for age and season 
 
 
 
Table 3: Adjusted incidence rate ratios of first myocardial infarction in risk periods after a 
respiratory tract infection 
Risk period Number of events  IRR (95% CI)* IRR (95% CI) # 
1-3 days 36 4.26 (2.00-9.06) 4.25 (1.99-9.04) 
4-7 days 10 2.28 (1.03-5.54) 2.27 (1.03-5.55) 
8-14 days 7 1.30 (0.78-2.46) 1.29 (0.76-2.49) 
15-28 days 5 1.04 (0.69-2.81) 1.05 (0.68-2.46) 
29-91 days 4 1.05 (0.73-1.50) 1.03 (0.71-1.52) 
Baseline period 347 1.00 1.00 
*Incidence Rate Ratio adjusted for age                                  #Incidence Rate Ratio adjusted for age and season 
 
Table 4: Adjusted incidence rate ratios of first stroke in risk periods after respiratory tract 
infection  
Risk period Number of events  IRR (95% CI)* IRR (95% CI) # 
1-3 days 48 1.79 (1.20-3.53) 1.77 (1.15-3.56) 
4-7 days 13 1.59 (1.12-4.75) 1.58 (1.12-4.76) 
8-14 days 10 1.32 (0.96- 3.09) 1.29 (0.94-3.09) 
15-28 days 3 1.14 (0.79-4.15) 1.14 (0.77-4.17) 
29-91 days 4 0.98 (0.62-3.31) 0.95 (0.60-3.32) 
Baseline period 383 1.00 1.00 
*Incidence Rate Ratio adjusted for age          #Incidence Rate Ratio adjusted for age and season 
Table 5: Adjusted incidence rate ratios of a first cardiovascular event in risk periods after a 
respiratory tract infection excluding people with a co-existing diagnosis of COPD 
Risk period Number of events  IRR (95% CI)* 
1-3 days 42 2.38 (1.77-4.76) 
4-7 days 17 2.30 (1.46-3.89) 
8-14 days 5 1.61 (1.15-2.24) 
15-28 days 4 1.36 (0.67-2.76) 
29-91 days 2 0.97 (0.55-2.16) 
Baseline period 352 1.00  
*Incidence Rate Ratio adjusted for age  
 
Discussion 
Our population based study found that amongst people with non-CF bronchiectasis, a 
respiratory tract infection is strongly associated with a transient increase in the rate of 
incident cardiovascular events. The rate of first cardiovascular events was over two-fold 
higher in the first three days following a respiratory tract infection and remained almost 
double up to two weeks after, compared to periods without infection. While the rates of both 
first MI and stroke were elevated after a respiratory tract infection, the effect was most 
pronounced with first MI. The impact of respiratory tract infection on cardiovascular risk was 
greatest in the first week after the infection, suggesting a narrow window for risk factor 
modification. Although a substantial number of individuals with bronchiectasis in our 
population also had a co-existing record of COPD, our secondary analyses showed that the 
association persists after excluding this subset of people.  The age-standardized (standardized 
to the 2004 UK population) rate of respiratory tract infections in the entire bronchiectasis 
cohort (n=26,415) was 632.7 per 1000 person years. This was approximately six times higher 
than the age-standardized rate of community acquired lower respiratory tract infections in 
the general population.[13] Hence the relative risk of a cardiovascular event occurring 
following a respiratory tract infection in a patient with bronchiectasis is six-fold higher than 
the relative risk of a cardiovascular event occurring following a systemic respiratory tract 
infection in the general population.  
One of the strengths of our study is the large population of people with bronchiectasis and 
length of our observation period, which enabled us to quantify the risk of incident 
cardiovascular events after a respiratory tract infection.  An advantage of the self-controlled 
case series method is that it eliminates confounding by factors that vary between individuals 
such as smoking, hypertension, hyperlipidemia and diabetes mellitus, due to the fact that 
each person acts as their own control.[18] Furthermore, within-comparison between time 
periods relative to the exposure also removes the possibility of reverse causation.  It is 
possible that there is some misclassification between cardiovascular and infective events, 
however this is unlikely to account for the relationship we have seen in this study. In addition 
to the above, all key assumptions of the self-controlled case series methodology were met. 
We only used first time diagnoses of cardiovascular events as the risk of a subsequent event 
is likely to be different to the first.  Studies have established the validity of medical diagnoses 
within CPRD to be high [10, 19] and the use of prospectively collected information from 
electronic primary care records minimizes the potential of recall or observer bias.  
Our study has a number of limitations that need to be taken into consideration. Although 
we have studied a UK bronchiectasis population, the results are likely to be generalizable to 
other bronchiectasis populations worldwide, particularly in countries where the etiology of 
bronchiectasis is similar to the UK. [20] A potential limitation is the validity of diagnosis of 
bronchiectasis. Although we were unable to validate the diagnosis of bronchiectasis, only a 
small number of Read codes that have previously been published [1] were used to identify 
people with bronchiectasis. 70.7% of bronchiectasis patients who had a CV event also had a 
respiratory tract infection, suggesting that around one third of the initial cohort did not have 
clinically significant bronchiectasis. This is in keeping with previous studies and likely due to 
the increase in CT scans occurring in older individuals leading to a diagnosis of non-clinically 
significant disease.  
In order to improve the specificity of our bronchiectasis population, we excluded anyone who 
was under 18 years of age at time of diagnosis of bronchiectasis and those who also had a 
recorded diagnosis of cystic fibrosis.  As we did not have access to radiological information 
from our cohort, it is not possible to confirm if the diagnosis of bronchiectasis was made 
according to current guidelines. However, bronchiectasis is usually diagnosed in a secondary 
care setting after  patients have had radiological confirmation with a computed tomography 
scan, as demonstrated by the recent British Thoracic Society bronchiectasis audit.[20] 
Therefore it is unlikely that a diagnosis of bronchiectasis would present in primary care 
records without confirmation from healthcare providers in secondary care. Further 
reassurance of the external validity of diagnosis of bronchiectasis is supported by the fact that 
the demographic features of our cohort are consistent with the UK population of patients 
with bronchiectasis.[21-23] Our bronchiectasis cohort is also likely to represent individuals 
with a diagnosis of bronchiectasis in their primary care records across the disease spectrum. 
It is possible that by excluding people with bronchiectasis before the age of 18 that we have 
disproportionately excluded those with primary ciliary dyskinesia making the results less 
applicable to that group, however we are not able to test this.  
Another potential limitation of our study is we used date of diagnosis of respiratory tract 
infection rather than date of onset, which could not be determined accurately. This is likely 
to result in underestimation of the duration of the increased risk of first MI or stroke. 
Furthermore, we will not have captured all respiratory tract infections in people with 
bronchiectasis as some patients may have rescue antibiotics at home to self-medicate at 
onset of symptoms. It is important to note that the exposure in our study was a respiratory 
tract infection that precipitated consultation with primary care, the severity of which will vary 
between individuals. We were unable to use the British Thoracic Society guideline definition 
of infective exacerbation of bronchiectasis [24] as our exposure definition due to the small 
number of people who met these criteria. We also did not have information on disease 
severity or secondary care records to assess if disease severity or hospitalization influenced 
the effect of respiratory tract infections on the risk of incident cardiovascular outcomes. 
Therefore it is likely that our findings are actually an underestimate of the risk of 
cardiovascular disease following airway infection in people with bronchiectasis.   
To our knowledge, this is the first study to demonstrate that amongst a population of people 
with bronchiectasis, an acute respiratory tract infection is associated with a transient 
increased risk of incident cardiovascular outcomes.  Our findings are consistent with studies 
that have shown that in the general population[3-5] and amongst people with COPD[6], the 
risk of MI and stroke are higher after a respiratory tract infection. Using routine primary care 
data, studies have shown that the relative risk for both MI[3, 4] and stroke[4] were 
substantially higher in the first few days after a respiratory tract infection, especially following 
influenza infection.[25] More recently, a study using two separate community based cohorts 
demonstrated that episodes of pneumonia that resulted in a hospital admission was 
associated with a short and longer term risk of cardiovascular disease.[26] It has also been 
demonstrated that the risk of MI and stroke is higher following an exacerbation of COPD. [6] 
The increased risk of cardiovascular outcomes following respiratory tract infections in 
bronchiectasis may be due to a number of reasons; one of which is shared risk factors such as 
hypoxia and transient increase in systemic inflammation. It has been hypothesized that 
respiratory tract infections contribute to progression of atherosclerotic plaques[27], coupled 
with elevated levels of inflammatory cytokines[28] precipitate cardiovascular events. Arterial 
stiffness has been shown to rise acutely during infective exacerbations of COPD[29], 
increasing the risk of MI and stroke following airway infection in this population. Aortic 
stiffness has previously been shown to be elevated in people with bronchiectasis [30] raising 
the possibility that this mechanism contributes to the increased risk in cardiovascular 
outcomes seen in our study.  
51% of people with bronchiectasis in our cohort also had a diagnosis of COPD, which is also 
associated with increased risk of cardiovascular disease. However, our secondary analyses, 
excluding individuals co-existing diagnoses of COPD suggests that the increased 
cardiovascular risk following infection still persists.   
In conclusion, our study has quantified the increased risk of incident cardiovascular outcomes, 
which amongst people with bronchiectasis is more than double in the first seven days 
following a respiratory tract infection compared to periods without an infection.  This 
increased relative cardiovascular risk in people with bronchiectasis is substantially higher 
compared to the risk of MI or stroke following community acquired respiratory tract 
infections in the general population. These data suggest recurrent respiratory tract infections 
contribute to the increased cardiovascular comorbidities in people with bronchiectasis and 
clinical trials of targeted anti-platelet or statins into prevention of respiratory infection 
related vascular events are warranted.   
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